<DOC>
	<DOCNO>NCT00035412</DOCNO>
	<brief_summary>The purpose study determine effectiveness St. John ’ Wort compare placebo ( inactive substance ) treatment outpatient social phobia .</brief_summary>
	<brief_title>St. John 's Wort Versus Placebo Social Phobia</brief_title>
	<detailed_description>Social Phobia prevalent debilitate condition , lifetime prevalence rate 13.3 percent . Socially phobic patient find functionally impaired area education , employment social relationship , poor quality life , increase suicidal ideation psychiatric comorbidity . Double-blind study find benzodiazepine , selective non-selective MAOI inhibitor , several SSRIs , anticonvulsants pregabalin gabapentin effective . However , side effect compound suggests need well tolerate compound , e.g. , paroxetine multi-center trial ( drug FDA approve indication ) , 27 percent report somnolence , 26 percent nausea , 37 percent male report delayed ejaculation ; 34 percent patient discontinue trial early . There considerable worldwide interest St. John 's Wort ( SJW ) ( Hypericum perforatum ) treatment mild moderate depression . There 23 randomized trial suggest SJW effective placebo treatment outpatient mild moderate depression . SJW well tolerate mild side effect observe 2.5 percent case large ( 3250 patient ) drug monitoring study . Pharmacokinetic study find Hypericum affinity serotonin , dopamine GABA alpha GABA beta receptor , implicate social phobia , thus suggestion SJW may effective disorder . This 12-week , double blind , placebo-controlled trial , design generate effect size data use determine sample size need power definitive study . Forty patient randomize either SJW ( LI 160 ) match placebo . This flexible-dose design , start 300 mg tid maximum 1800 mg total per day . An intent-to-treat analysis employ . Subjects evaluate weekly two week , bi-weekly thereafter . The primary outcome measure change baseline endpoint Liebowitz Social Anxiety Scale .</detailed_description>
	<mesh_term>Phobic Disorders</mesh_term>
	<criteria>Female patient : least 2 year postmenopausal , surgically sterile , practice medically acceptable method contraception . Meets DSMIV criterion Social Phobia , generalize subtype , last 12 month duration ( phone screen determine ) Primary diagnosis major depression , dysthymia , panic disorder , schizophrenia , schizoaffective disorder , bipolar disorder , PTSD Substance abuse dependence past 6 month Vascular dementia primary degenerative dementia Alzheimer ’ type Treatment MAOIs , TCAs , SSRIs , venlafaxine , nefazodone , remeron , citalopram , bupropion within 14 day first visit . Fluoxetine within 14 day first visit . Failure respond least two adequate antidepressant trial social anxiety . Investigational drug within 30 day baseline Known allergy hypersensitivity St. John ’ Wort Currently behavior therapy Social Phobia ALL INQUIRIES WILL UNDERGO A PHONE SCREENING TO DETERMINE WHETHER THEY MEET ELIGIBLITY REQUIREMENTS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Social phobia</keyword>
	<keyword>Social anxiety</keyword>
	<keyword>Anxiety</keyword>
	<keyword>St. John ’ Wort</keyword>
	<keyword>Wisconsin</keyword>
	<keyword>Psychiatric</keyword>
	<keyword>Mental health</keyword>
</DOC>